MOL THER-ONCOLYTICS 润色咨询

Molecular Therapy-Oncolytics

出版年份：暂无数据 年文章数：598 投稿命中率： 开通期刊会员，数据随心看

出版周期：暂无数据 自引率：3.3% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=1106908, encodeId=35ad11069082c, content=审稿人怎么利用关键词审稿？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Tue Dec 28 14:52:53 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1081565, encodeId=858010815653e, content=现在在投稿under review靠近6周了，11.8开始under review，12.13更新状态还是under review不知道各位碰见过这种状态没有。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99745438474, createdName=ms1000000488569756, createdTime=Sat Dec 18 16:41:44 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007655, encodeId=153e100e655c6, content=3月份投稿，8月13日接受，历经5个月，中间经历了大修和预接受这两种状态。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0fda5217760, createdName=14772c6cm60暂无昵称, createdTime=Fri Aug 13 16:27:41 CST 2021, time=2021-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999610, encodeId=3e419996105f, content=这个杂志奔着顶刊去的，文章水平很高！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa371702984, createdName=malonglee, createdTime=Thu Jul 15 00:26:11 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057068, encodeId=a02b105e06855, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享：7.21投稿 8.31第二次under review 到至今10.3，朋友们 你们是多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/2a25e58f011d93078d80a80708872da9.jpg, createdBy=bb3f5116851, createdName=Lord Megatron, createdTime=Sun Oct 03 09:33:17 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051143, encodeId=22ab105114398, content=投稿命中率:5.0<br>经验分享：MTNA初审后建议转投MTO，不知道机会大不大？感觉杂志的效率没有那么高？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f20c5131031, createdName=D-Z, createdTime=Tue Sep 14 15:20:24 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919900, encodeId=5689919900c2, content=审稿速度:2.0 | 投稿命中率:50.0 | 审稿费用:3500.0<br>偏重的研究方向：肿瘤<br>经验分享：一开始投了Molecular Therapy Nuclical acid，编辑拒稿然后建议转投这个。后面是时间线。<br><br>Jan 25, 2021 PDF Built and Requires Approval<br>Jan 11, 2021 Editor Decision - Minor Revision<br>Jan 08, 2021 Author Notice of Manuscript Number<br>Dec 31, 2020 Author Submits New Manuscript Confirmation<br>Dec 24, 2020 PDF Built and Requires Approval<br>Dec 23, 2020 Author - Transfer Sent Back to Author (Automatic)<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36571969413, createdName=leoscar, createdTime=Tue Jan 26 01:44:27 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948606, encodeId=a3199486068a, content=请问这个杂志需要审稿费吗？？？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=58865396532, createdName=RH–洛晴川, createdTime=Tue Mar 16 11:07:18 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=591266, encodeId=9bae59126629, content=最近非常慢。两个月修回<span class="quote">ahrrrrr 2020-05-10 发表::<br>大家最近有投稿吗，投稿多久会分配稿号啊</span><span class="quote">rrr136 2020-05-10 00:00:00 发表:<br>大家最近有投稿吗，投稿多久会分配稿号啊</span>, beContent=ahrrrrr 2020-05-10 发表:: 大家最近有投稿吗，投稿多久会分配稿号啊, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1b72231756, createdName=121255c0m87暂无昵称, createdTime=Wed May 20 00:00:00 CST 2020, time=2020-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566469, encodeId=f2c0566469c7, content=Good，今年估计5.8分，还会涨，cancer领域将有一席之地, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150826/IMG55DD4550988EA1332.jpg, createdBy=3f88101689, createdName=princesun083, createdTime=Mon Feb 04 00:00:00 CST 2019, time=2019-02-04, status=1, ipAttribution=)]
    2021-12-28 msSSSSSD

    审稿人怎么利用关键词审稿？

    1

    展开1条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=1106908, encodeId=35ad11069082c, content=审稿人怎么利用关键词审稿？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Tue Dec 28 14:52:53 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1081565, encodeId=858010815653e, content=现在在投稿under review靠近6周了，11.8开始under review，12.13更新状态还是under review不知道各位碰见过这种状态没有。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99745438474, createdName=ms1000000488569756, createdTime=Sat Dec 18 16:41:44 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007655, encodeId=153e100e655c6, content=3月份投稿，8月13日接受，历经5个月，中间经历了大修和预接受这两种状态。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0fda5217760, createdName=14772c6cm60暂无昵称, createdTime=Fri Aug 13 16:27:41 CST 2021, time=2021-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999610, encodeId=3e419996105f, content=这个杂志奔着顶刊去的，文章水平很高！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa371702984, createdName=malonglee, createdTime=Thu Jul 15 00:26:11 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057068, encodeId=a02b105e06855, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享：7.21投稿 8.31第二次under review 到至今10.3，朋友们 你们是多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/2a25e58f011d93078d80a80708872da9.jpg, createdBy=bb3f5116851, createdName=Lord Megatron, createdTime=Sun Oct 03 09:33:17 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051143, encodeId=22ab105114398, content=投稿命中率:5.0<br>经验分享：MTNA初审后建议转投MTO，不知道机会大不大？感觉杂志的效率没有那么高？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f20c5131031, createdName=D-Z, createdTime=Tue Sep 14 15:20:24 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919900, encodeId=5689919900c2, content=审稿速度:2.0 | 投稿命中率:50.0 | 审稿费用:3500.0<br>偏重的研究方向：肿瘤<br>经验分享：一开始投了Molecular Therapy Nuclical acid，编辑拒稿然后建议转投这个。后面是时间线。<br><br>Jan 25, 2021 PDF Built and Requires Approval<br>Jan 11, 2021 Editor Decision - Minor Revision<br>Jan 08, 2021 Author Notice of Manuscript Number<br>Dec 31, 2020 Author Submits New Manuscript Confirmation<br>Dec 24, 2020 PDF Built and Requires Approval<br>Dec 23, 2020 Author - Transfer Sent Back to Author (Automatic)<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36571969413, createdName=leoscar, createdTime=Tue Jan 26 01:44:27 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948606, encodeId=a3199486068a, content=请问这个杂志需要审稿费吗？？？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=58865396532, createdName=RH–洛晴川, createdTime=Tue Mar 16 11:07:18 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=591266, encodeId=9bae59126629, content=最近非常慢。两个月修回<span class="quote">ahrrrrr 2020-05-10 发表::<br>大家最近有投稿吗，投稿多久会分配稿号啊</span><span class="quote">rrr136 2020-05-10 00:00:00 发表:<br>大家最近有投稿吗，投稿多久会分配稿号啊</span>, beContent=ahrrrrr 2020-05-10 发表:: 大家最近有投稿吗，投稿多久会分配稿号啊, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1b72231756, createdName=121255c0m87暂无昵称, createdTime=Wed May 20 00:00:00 CST 2020, time=2020-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566469, encodeId=f2c0566469c7, content=Good，今年估计5.8分，还会涨，cancer领域将有一席之地, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150826/IMG55DD4550988EA1332.jpg, createdBy=3f88101689, createdName=princesun083, createdTime=Mon Feb 04 00:00:00 CST 2019, time=2019-02-04, status=1, ipAttribution=)]
    2021-12-18 ms1000000488569756

    现在在投稿under review靠近6周了，11.8开始under review，12.13更新状态还是under review不知道各位碰见过这种状态没有。

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1106908, encodeId=35ad11069082c, content=审稿人怎么利用关键词审稿？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Tue Dec 28 14:52:53 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1081565, encodeId=858010815653e, content=现在在投稿under review靠近6周了，11.8开始under review，12.13更新状态还是under review不知道各位碰见过这种状态没有。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99745438474, createdName=ms1000000488569756, createdTime=Sat Dec 18 16:41:44 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007655, encodeId=153e100e655c6, content=3月份投稿，8月13日接受，历经5个月，中间经历了大修和预接受这两种状态。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0fda5217760, createdName=14772c6cm60暂无昵称, createdTime=Fri Aug 13 16:27:41 CST 2021, time=2021-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999610, encodeId=3e419996105f, content=这个杂志奔着顶刊去的，文章水平很高！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa371702984, createdName=malonglee, createdTime=Thu Jul 15 00:26:11 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057068, encodeId=a02b105e06855, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享：7.21投稿 8.31第二次under review 到至今10.3，朋友们 你们是多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/2a25e58f011d93078d80a80708872da9.jpg, createdBy=bb3f5116851, createdName=Lord Megatron, createdTime=Sun Oct 03 09:33:17 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051143, encodeId=22ab105114398, content=投稿命中率:5.0<br>经验分享：MTNA初审后建议转投MTO，不知道机会大不大？感觉杂志的效率没有那么高？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f20c5131031, createdName=D-Z, createdTime=Tue Sep 14 15:20:24 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919900, encodeId=5689919900c2, content=审稿速度:2.0 | 投稿命中率:50.0 | 审稿费用:3500.0<br>偏重的研究方向：肿瘤<br>经验分享：一开始投了Molecular Therapy Nuclical acid，编辑拒稿然后建议转投这个。后面是时间线。<br><br>Jan 25, 2021 PDF Built and Requires Approval<br>Jan 11, 2021 Editor Decision - Minor Revision<br>Jan 08, 2021 Author Notice of Manuscript Number<br>Dec 31, 2020 Author Submits New Manuscript Confirmation<br>Dec 24, 2020 PDF Built and Requires Approval<br>Dec 23, 2020 Author - Transfer Sent Back to Author (Automatic)<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36571969413, createdName=leoscar, createdTime=Tue Jan 26 01:44:27 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948606, encodeId=a3199486068a, content=请问这个杂志需要审稿费吗？？？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=58865396532, createdName=RH–洛晴川, createdTime=Tue Mar 16 11:07:18 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=591266, encodeId=9bae59126629, content=最近非常慢。两个月修回<span class="quote">ahrrrrr 2020-05-10 发表::<br>大家最近有投稿吗，投稿多久会分配稿号啊</span><span class="quote">rrr136 2020-05-10 00:00:00 发表:<br>大家最近有投稿吗，投稿多久会分配稿号啊</span>, beContent=ahrrrrr 2020-05-10 发表:: 大家最近有投稿吗，投稿多久会分配稿号啊, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1b72231756, createdName=121255c0m87暂无昵称, createdTime=Wed May 20 00:00:00 CST 2020, time=2020-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566469, encodeId=f2c0566469c7, content=Good，今年估计5.8分，还会涨，cancer领域将有一席之地, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150826/IMG55DD4550988EA1332.jpg, createdBy=3f88101689, createdName=princesun083, createdTime=Mon Feb 04 00:00:00 CST 2019, time=2019-02-04, status=1, ipAttribution=)]
    2021-08-13 14772c6cm60暂无昵称

    3月份投稿，8月13日接受，历经5个月，中间经历了大修和预接受这两种状态。

    1

    展开1条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=1106908, encodeId=35ad11069082c, content=审稿人怎么利用关键词审稿？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Tue Dec 28 14:52:53 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1081565, encodeId=858010815653e, content=现在在投稿under review靠近6周了，11.8开始under review，12.13更新状态还是under review不知道各位碰见过这种状态没有。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99745438474, createdName=ms1000000488569756, createdTime=Sat Dec 18 16:41:44 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007655, encodeId=153e100e655c6, content=3月份投稿，8月13日接受，历经5个月，中间经历了大修和预接受这两种状态。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0fda5217760, createdName=14772c6cm60暂无昵称, createdTime=Fri Aug 13 16:27:41 CST 2021, time=2021-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999610, encodeId=3e419996105f, content=这个杂志奔着顶刊去的，文章水平很高！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa371702984, createdName=malonglee, createdTime=Thu Jul 15 00:26:11 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057068, encodeId=a02b105e06855, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享：7.21投稿 8.31第二次under review 到至今10.3，朋友们 你们是多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/2a25e58f011d93078d80a80708872da9.jpg, createdBy=bb3f5116851, createdName=Lord Megatron, createdTime=Sun Oct 03 09:33:17 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051143, encodeId=22ab105114398, content=投稿命中率:5.0<br>经验分享：MTNA初审后建议转投MTO，不知道机会大不大？感觉杂志的效率没有那么高？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f20c5131031, createdName=D-Z, createdTime=Tue Sep 14 15:20:24 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919900, encodeId=5689919900c2, content=审稿速度:2.0 | 投稿命中率:50.0 | 审稿费用:3500.0<br>偏重的研究方向：肿瘤<br>经验分享：一开始投了Molecular Therapy Nuclical acid，编辑拒稿然后建议转投这个。后面是时间线。<br><br>Jan 25, 2021 PDF Built and Requires Approval<br>Jan 11, 2021 Editor Decision - Minor Revision<br>Jan 08, 2021 Author Notice of Manuscript Number<br>Dec 31, 2020 Author Submits New Manuscript Confirmation<br>Dec 24, 2020 PDF Built and Requires Approval<br>Dec 23, 2020 Author - Transfer Sent Back to Author (Automatic)<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36571969413, createdName=leoscar, createdTime=Tue Jan 26 01:44:27 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948606, encodeId=a3199486068a, content=请问这个杂志需要审稿费吗？？？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=58865396532, createdName=RH–洛晴川, createdTime=Tue Mar 16 11:07:18 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=591266, encodeId=9bae59126629, content=最近非常慢。两个月修回<span class="quote">ahrrrrr 2020-05-10 发表::<br>大家最近有投稿吗，投稿多久会分配稿号啊</span><span class="quote">rrr136 2020-05-10 00:00:00 发表:<br>大家最近有投稿吗，投稿多久会分配稿号啊</span>, beContent=ahrrrrr 2020-05-10 发表:: 大家最近有投稿吗，投稿多久会分配稿号啊, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1b72231756, createdName=121255c0m87暂无昵称, createdTime=Wed May 20 00:00:00 CST 2020, time=2020-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566469, encodeId=f2c0566469c7, content=Good，今年估计5.8分，还会涨，cancer领域将有一席之地, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150826/IMG55DD4550988EA1332.jpg, createdBy=3f88101689, createdName=princesun083, createdTime=Mon Feb 04 00:00:00 CST 2019, time=2019-02-04, status=1, ipAttribution=)]
    2021-07-15 malonglee

    这个杂志奔着顶刊去的，文章水平很高！

    6

    展开6条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=1106908, encodeId=35ad11069082c, content=审稿人怎么利用关键词审稿？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Tue Dec 28 14:52:53 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1081565, encodeId=858010815653e, content=现在在投稿under review靠近6周了，11.8开始under review，12.13更新状态还是under review不知道各位碰见过这种状态没有。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99745438474, createdName=ms1000000488569756, createdTime=Sat Dec 18 16:41:44 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007655, encodeId=153e100e655c6, content=3月份投稿，8月13日接受，历经5个月，中间经历了大修和预接受这两种状态。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0fda5217760, createdName=14772c6cm60暂无昵称, createdTime=Fri Aug 13 16:27:41 CST 2021, time=2021-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999610, encodeId=3e419996105f, content=这个杂志奔着顶刊去的，文章水平很高！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa371702984, createdName=malonglee, createdTime=Thu Jul 15 00:26:11 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057068, encodeId=a02b105e06855, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享：7.21投稿 8.31第二次under review 到至今10.3，朋友们 你们是多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/2a25e58f011d93078d80a80708872da9.jpg, createdBy=bb3f5116851, createdName=Lord Megatron, createdTime=Sun Oct 03 09:33:17 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051143, encodeId=22ab105114398, content=投稿命中率:5.0<br>经验分享：MTNA初审后建议转投MTO，不知道机会大不大？感觉杂志的效率没有那么高？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f20c5131031, createdName=D-Z, createdTime=Tue Sep 14 15:20:24 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919900, encodeId=5689919900c2, content=审稿速度:2.0 | 投稿命中率:50.0 | 审稿费用:3500.0<br>偏重的研究方向：肿瘤<br>经验分享：一开始投了Molecular Therapy Nuclical acid，编辑拒稿然后建议转投这个。后面是时间线。<br><br>Jan 25, 2021 PDF Built and Requires Approval<br>Jan 11, 2021 Editor Decision - Minor Revision<br>Jan 08, 2021 Author Notice of Manuscript Number<br>Dec 31, 2020 Author Submits New Manuscript Confirmation<br>Dec 24, 2020 PDF Built and Requires Approval<br>Dec 23, 2020 Author - Transfer Sent Back to Author (Automatic)<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36571969413, createdName=leoscar, createdTime=Tue Jan 26 01:44:27 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948606, encodeId=a3199486068a, content=请问这个杂志需要审稿费吗？？？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=58865396532, createdName=RH–洛晴川, createdTime=Tue Mar 16 11:07:18 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=591266, encodeId=9bae59126629, content=最近非常慢。两个月修回<span class="quote">ahrrrrr 2020-05-10 发表::<br>大家最近有投稿吗，投稿多久会分配稿号啊</span><span class="quote">rrr136 2020-05-10 00:00:00 发表:<br>大家最近有投稿吗，投稿多久会分配稿号啊</span>, beContent=ahrrrrr 2020-05-10 发表:: 大家最近有投稿吗，投稿多久会分配稿号啊, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1b72231756, createdName=121255c0m87暂无昵称, createdTime=Wed May 20 00:00:00 CST 2020, time=2020-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566469, encodeId=f2c0566469c7, content=Good，今年估计5.8分，还会涨，cancer领域将有一席之地, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150826/IMG55DD4550988EA1332.jpg, createdBy=3f88101689, createdName=princesun083, createdTime=Mon Feb 04 00:00:00 CST 2019, time=2019-02-04, status=1, ipAttribution=)]
    2021-10-03 Lord Megatron

    审稿速度:3.0 | 投稿命中率:25.0
    经验分享：7.21投稿 8.31第二次under review 到至今10.3，朋友们 你们是多久啊

    2

    展开2条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=1106908, encodeId=35ad11069082c, content=审稿人怎么利用关键词审稿？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Tue Dec 28 14:52:53 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1081565, encodeId=858010815653e, content=现在在投稿under review靠近6周了，11.8开始under review，12.13更新状态还是under review不知道各位碰见过这种状态没有。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99745438474, createdName=ms1000000488569756, createdTime=Sat Dec 18 16:41:44 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007655, encodeId=153e100e655c6, content=3月份投稿，8月13日接受，历经5个月，中间经历了大修和预接受这两种状态。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0fda5217760, createdName=14772c6cm60暂无昵称, createdTime=Fri Aug 13 16:27:41 CST 2021, time=2021-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999610, encodeId=3e419996105f, content=这个杂志奔着顶刊去的，文章水平很高！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa371702984, createdName=malonglee, createdTime=Thu Jul 15 00:26:11 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057068, encodeId=a02b105e06855, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享：7.21投稿 8.31第二次under review 到至今10.3，朋友们 你们是多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/2a25e58f011d93078d80a80708872da9.jpg, createdBy=bb3f5116851, createdName=Lord Megatron, createdTime=Sun Oct 03 09:33:17 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051143, encodeId=22ab105114398, content=投稿命中率:5.0<br>经验分享：MTNA初审后建议转投MTO，不知道机会大不大？感觉杂志的效率没有那么高？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f20c5131031, createdName=D-Z, createdTime=Tue Sep 14 15:20:24 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919900, encodeId=5689919900c2, content=审稿速度:2.0 | 投稿命中率:50.0 | 审稿费用:3500.0<br>偏重的研究方向：肿瘤<br>经验分享：一开始投了Molecular Therapy Nuclical acid，编辑拒稿然后建议转投这个。后面是时间线。<br><br>Jan 25, 2021 PDF Built and Requires Approval<br>Jan 11, 2021 Editor Decision - Minor Revision<br>Jan 08, 2021 Author Notice of Manuscript Number<br>Dec 31, 2020 Author Submits New Manuscript Confirmation<br>Dec 24, 2020 PDF Built and Requires Approval<br>Dec 23, 2020 Author - Transfer Sent Back to Author (Automatic)<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36571969413, createdName=leoscar, createdTime=Tue Jan 26 01:44:27 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948606, encodeId=a3199486068a, content=请问这个杂志需要审稿费吗？？？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=58865396532, createdName=RH–洛晴川, createdTime=Tue Mar 16 11:07:18 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=591266, encodeId=9bae59126629, content=最近非常慢。两个月修回<span class="quote">ahrrrrr 2020-05-10 发表::<br>大家最近有投稿吗，投稿多久会分配稿号啊</span><span class="quote">rrr136 2020-05-10 00:00:00 发表:<br>大家最近有投稿吗，投稿多久会分配稿号啊</span>, beContent=ahrrrrr 2020-05-10 发表:: 大家最近有投稿吗，投稿多久会分配稿号啊, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1b72231756, createdName=121255c0m87暂无昵称, createdTime=Wed May 20 00:00:00 CST 2020, time=2020-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566469, encodeId=f2c0566469c7, content=Good，今年估计5.8分，还会涨，cancer领域将有一席之地, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150826/IMG55DD4550988EA1332.jpg, createdBy=3f88101689, createdName=princesun083, createdTime=Mon Feb 04 00:00:00 CST 2019, time=2019-02-04, status=1, ipAttribution=)]
    2021-09-14 D-Z

    投稿命中率:5.0
    经验分享：MTNA初审后建议转投MTO，不知道机会大不大？感觉杂志的效率没有那么高？

    1

    展开1条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=1106908, encodeId=35ad11069082c, content=审稿人怎么利用关键词审稿？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Tue Dec 28 14:52:53 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1081565, encodeId=858010815653e, content=现在在投稿under review靠近6周了，11.8开始under review，12.13更新状态还是under review不知道各位碰见过这种状态没有。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99745438474, createdName=ms1000000488569756, createdTime=Sat Dec 18 16:41:44 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007655, encodeId=153e100e655c6, content=3月份投稿，8月13日接受，历经5个月，中间经历了大修和预接受这两种状态。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0fda5217760, createdName=14772c6cm60暂无昵称, createdTime=Fri Aug 13 16:27:41 CST 2021, time=2021-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999610, encodeId=3e419996105f, content=这个杂志奔着顶刊去的，文章水平很高！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa371702984, createdName=malonglee, createdTime=Thu Jul 15 00:26:11 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057068, encodeId=a02b105e06855, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享：7.21投稿 8.31第二次under review 到至今10.3，朋友们 你们是多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/2a25e58f011d93078d80a80708872da9.jpg, createdBy=bb3f5116851, createdName=Lord Megatron, createdTime=Sun Oct 03 09:33:17 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051143, encodeId=22ab105114398, content=投稿命中率:5.0<br>经验分享：MTNA初审后建议转投MTO，不知道机会大不大？感觉杂志的效率没有那么高？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f20c5131031, createdName=D-Z, createdTime=Tue Sep 14 15:20:24 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919900, encodeId=5689919900c2, content=审稿速度:2.0 | 投稿命中率:50.0 | 审稿费用:3500.0<br>偏重的研究方向：肿瘤<br>经验分享：一开始投了Molecular Therapy Nuclical acid，编辑拒稿然后建议转投这个。后面是时间线。<br><br>Jan 25, 2021 PDF Built and Requires Approval<br>Jan 11, 2021 Editor Decision - Minor Revision<br>Jan 08, 2021 Author Notice of Manuscript Number<br>Dec 31, 2020 Author Submits New Manuscript Confirmation<br>Dec 24, 2020 PDF Built and Requires Approval<br>Dec 23, 2020 Author - Transfer Sent Back to Author (Automatic)<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36571969413, createdName=leoscar, createdTime=Tue Jan 26 01:44:27 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948606, encodeId=a3199486068a, content=请问这个杂志需要审稿费吗？？？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=58865396532, createdName=RH–洛晴川, createdTime=Tue Mar 16 11:07:18 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=591266, encodeId=9bae59126629, content=最近非常慢。两个月修回<span class="quote">ahrrrrr 2020-05-10 发表::<br>大家最近有投稿吗，投稿多久会分配稿号啊</span><span class="quote">rrr136 2020-05-10 00:00:00 发表:<br>大家最近有投稿吗，投稿多久会分配稿号啊</span>, beContent=ahrrrrr 2020-05-10 发表:: 大家最近有投稿吗，投稿多久会分配稿号啊, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1b72231756, createdName=121255c0m87暂无昵称, createdTime=Wed May 20 00:00:00 CST 2020, time=2020-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566469, encodeId=f2c0566469c7, content=Good，今年估计5.8分，还会涨，cancer领域将有一席之地, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150826/IMG55DD4550988EA1332.jpg, createdBy=3f88101689, createdName=princesun083, createdTime=Mon Feb 04 00:00:00 CST 2019, time=2019-02-04, status=1, ipAttribution=)]
    2021-01-26 leoscar

    审稿速度:2.0 | 投稿命中率:50.0 | 审稿费用:3500.0
    偏重的研究方向：肿瘤
    经验分享：一开始投了Molecular Therapy Nuclical acid，编辑拒稿然后建议转投这个。后面是时间线。

    Jan 25, 2021 PDF Built and Requires Approval
    Jan 11, 2021 Editor Decision - Minor Revision
    Jan 08, 2021 Author Notice of Manuscript Number
    Dec 31, 2020 Author Submits New Manuscript Confirmation
    Dec 24, 2020 PDF Built and Requires Approval
    Dec 23, 2020 Author - Transfer Sent Back to Author (Automatic)

    2

    展开2条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=1106908, encodeId=35ad11069082c, content=审稿人怎么利用关键词审稿？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Tue Dec 28 14:52:53 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1081565, encodeId=858010815653e, content=现在在投稿under review靠近6周了，11.8开始under review，12.13更新状态还是under review不知道各位碰见过这种状态没有。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99745438474, createdName=ms1000000488569756, createdTime=Sat Dec 18 16:41:44 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007655, encodeId=153e100e655c6, content=3月份投稿，8月13日接受，历经5个月，中间经历了大修和预接受这两种状态。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0fda5217760, createdName=14772c6cm60暂无昵称, createdTime=Fri Aug 13 16:27:41 CST 2021, time=2021-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999610, encodeId=3e419996105f, content=这个杂志奔着顶刊去的，文章水平很高！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa371702984, createdName=malonglee, createdTime=Thu Jul 15 00:26:11 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057068, encodeId=a02b105e06855, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享：7.21投稿 8.31第二次under review 到至今10.3，朋友们 你们是多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/2a25e58f011d93078d80a80708872da9.jpg, createdBy=bb3f5116851, createdName=Lord Megatron, createdTime=Sun Oct 03 09:33:17 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051143, encodeId=22ab105114398, content=投稿命中率:5.0<br>经验分享：MTNA初审后建议转投MTO，不知道机会大不大？感觉杂志的效率没有那么高？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f20c5131031, createdName=D-Z, createdTime=Tue Sep 14 15:20:24 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919900, encodeId=5689919900c2, content=审稿速度:2.0 | 投稿命中率:50.0 | 审稿费用:3500.0<br>偏重的研究方向：肿瘤<br>经验分享：一开始投了Molecular Therapy Nuclical acid，编辑拒稿然后建议转投这个。后面是时间线。<br><br>Jan 25, 2021 PDF Built and Requires Approval<br>Jan 11, 2021 Editor Decision - Minor Revision<br>Jan 08, 2021 Author Notice of Manuscript Number<br>Dec 31, 2020 Author Submits New Manuscript Confirmation<br>Dec 24, 2020 PDF Built and Requires Approval<br>Dec 23, 2020 Author - Transfer Sent Back to Author (Automatic)<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36571969413, createdName=leoscar, createdTime=Tue Jan 26 01:44:27 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948606, encodeId=a3199486068a, content=请问这个杂志需要审稿费吗？？？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=58865396532, createdName=RH–洛晴川, createdTime=Tue Mar 16 11:07:18 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=591266, encodeId=9bae59126629, content=最近非常慢。两个月修回<span class="quote">ahrrrrr 2020-05-10 发表::<br>大家最近有投稿吗，投稿多久会分配稿号啊</span><span class="quote">rrr136 2020-05-10 00:00:00 发表:<br>大家最近有投稿吗，投稿多久会分配稿号啊</span>, beContent=ahrrrrr 2020-05-10 发表:: 大家最近有投稿吗，投稿多久会分配稿号啊, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1b72231756, createdName=121255c0m87暂无昵称, createdTime=Wed May 20 00:00:00 CST 2020, time=2020-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566469, encodeId=f2c0566469c7, content=Good，今年估计5.8分，还会涨，cancer领域将有一席之地, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150826/IMG55DD4550988EA1332.jpg, createdBy=3f88101689, createdName=princesun083, createdTime=Mon Feb 04 00:00:00 CST 2019, time=2019-02-04, status=1, ipAttribution=)]
    2021-03-16 RH–洛晴川

    请问这个杂志需要审稿费吗？？？

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1106908, encodeId=35ad11069082c, content=审稿人怎么利用关键词审稿？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Tue Dec 28 14:52:53 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1081565, encodeId=858010815653e, content=现在在投稿under review靠近6周了，11.8开始under review，12.13更新状态还是under review不知道各位碰见过这种状态没有。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99745438474, createdName=ms1000000488569756, createdTime=Sat Dec 18 16:41:44 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007655, encodeId=153e100e655c6, content=3月份投稿，8月13日接受，历经5个月，中间经历了大修和预接受这两种状态。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0fda5217760, createdName=14772c6cm60暂无昵称, createdTime=Fri Aug 13 16:27:41 CST 2021, time=2021-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999610, encodeId=3e419996105f, content=这个杂志奔着顶刊去的，文章水平很高！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa371702984, createdName=malonglee, createdTime=Thu Jul 15 00:26:11 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057068, encodeId=a02b105e06855, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享：7.21投稿 8.31第二次under review 到至今10.3，朋友们 你们是多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/2a25e58f011d93078d80a80708872da9.jpg, createdBy=bb3f5116851, createdName=Lord Megatron, createdTime=Sun Oct 03 09:33:17 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051143, encodeId=22ab105114398, content=投稿命中率:5.0<br>经验分享：MTNA初审后建议转投MTO，不知道机会大不大？感觉杂志的效率没有那么高？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f20c5131031, createdName=D-Z, createdTime=Tue Sep 14 15:20:24 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919900, encodeId=5689919900c2, content=审稿速度:2.0 | 投稿命中率:50.0 | 审稿费用:3500.0<br>偏重的研究方向：肿瘤<br>经验分享：一开始投了Molecular Therapy Nuclical acid，编辑拒稿然后建议转投这个。后面是时间线。<br><br>Jan 25, 2021 PDF Built and Requires Approval<br>Jan 11, 2021 Editor Decision - Minor Revision<br>Jan 08, 2021 Author Notice of Manuscript Number<br>Dec 31, 2020 Author Submits New Manuscript Confirmation<br>Dec 24, 2020 PDF Built and Requires Approval<br>Dec 23, 2020 Author - Transfer Sent Back to Author (Automatic)<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36571969413, createdName=leoscar, createdTime=Tue Jan 26 01:44:27 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948606, encodeId=a3199486068a, content=请问这个杂志需要审稿费吗？？？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=58865396532, createdName=RH–洛晴川, createdTime=Tue Mar 16 11:07:18 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=591266, encodeId=9bae59126629, content=最近非常慢。两个月修回<span class="quote">ahrrrrr 2020-05-10 发表::<br>大家最近有投稿吗，投稿多久会分配稿号啊</span><span class="quote">rrr136 2020-05-10 00:00:00 发表:<br>大家最近有投稿吗，投稿多久会分配稿号啊</span>, beContent=ahrrrrr 2020-05-10 发表:: 大家最近有投稿吗，投稿多久会分配稿号啊, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1b72231756, createdName=121255c0m87暂无昵称, createdTime=Wed May 20 00:00:00 CST 2020, time=2020-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566469, encodeId=f2c0566469c7, content=Good，今年估计5.8分，还会涨，cancer领域将有一席之地, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150826/IMG55DD4550988EA1332.jpg, createdBy=3f88101689, createdName=princesun083, createdTime=Mon Feb 04 00:00:00 CST 2019, time=2019-02-04, status=1, ipAttribution=)]
    2020-05-20 121255c0m87暂无昵称

    最近非常慢。两个月修回ahrrrrr 2020-05-10 发表::
    大家最近有投稿吗，投稿多久会分配稿号啊    rrr136 2020-05-10 00:00:00 发表:
    大家最近有投稿吗，投稿多久会分配稿号啊

    ahrrrrr 2020-05-10 发表:: 大家最近有投稿吗，投稿多久会分配稿号啊

    4

    展开4条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=1106908, encodeId=35ad11069082c, content=审稿人怎么利用关键词审稿？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Tue Dec 28 14:52:53 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1081565, encodeId=858010815653e, content=现在在投稿under review靠近6周了，11.8开始under review，12.13更新状态还是under review不知道各位碰见过这种状态没有。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99745438474, createdName=ms1000000488569756, createdTime=Sat Dec 18 16:41:44 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007655, encodeId=153e100e655c6, content=3月份投稿，8月13日接受，历经5个月，中间经历了大修和预接受这两种状态。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0fda5217760, createdName=14772c6cm60暂无昵称, createdTime=Fri Aug 13 16:27:41 CST 2021, time=2021-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999610, encodeId=3e419996105f, content=这个杂志奔着顶刊去的，文章水平很高！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa371702984, createdName=malonglee, createdTime=Thu Jul 15 00:26:11 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057068, encodeId=a02b105e06855, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享：7.21投稿 8.31第二次under review 到至今10.3，朋友们 你们是多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/2a25e58f011d93078d80a80708872da9.jpg, createdBy=bb3f5116851, createdName=Lord Megatron, createdTime=Sun Oct 03 09:33:17 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051143, encodeId=22ab105114398, content=投稿命中率:5.0<br>经验分享：MTNA初审后建议转投MTO，不知道机会大不大？感觉杂志的效率没有那么高？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f20c5131031, createdName=D-Z, createdTime=Tue Sep 14 15:20:24 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919900, encodeId=5689919900c2, content=审稿速度:2.0 | 投稿命中率:50.0 | 审稿费用:3500.0<br>偏重的研究方向：肿瘤<br>经验分享：一开始投了Molecular Therapy Nuclical acid，编辑拒稿然后建议转投这个。后面是时间线。<br><br>Jan 25, 2021 PDF Built and Requires Approval<br>Jan 11, 2021 Editor Decision - Minor Revision<br>Jan 08, 2021 Author Notice of Manuscript Number<br>Dec 31, 2020 Author Submits New Manuscript Confirmation<br>Dec 24, 2020 PDF Built and Requires Approval<br>Dec 23, 2020 Author - Transfer Sent Back to Author (Automatic)<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36571969413, createdName=leoscar, createdTime=Tue Jan 26 01:44:27 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948606, encodeId=a3199486068a, content=请问这个杂志需要审稿费吗？？？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=58865396532, createdName=RH–洛晴川, createdTime=Tue Mar 16 11:07:18 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=591266, encodeId=9bae59126629, content=最近非常慢。两个月修回<span class="quote">ahrrrrr 2020-05-10 发表::<br>大家最近有投稿吗，投稿多久会分配稿号啊</span><span class="quote">rrr136 2020-05-10 00:00:00 发表:<br>大家最近有投稿吗，投稿多久会分配稿号啊</span>, beContent=ahrrrrr 2020-05-10 发表:: 大家最近有投稿吗，投稿多久会分配稿号啊, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1b72231756, createdName=121255c0m87暂无昵称, createdTime=Wed May 20 00:00:00 CST 2020, time=2020-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566469, encodeId=f2c0566469c7, content=Good，今年估计5.8分，还会涨，cancer领域将有一席之地, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150826/IMG55DD4550988EA1332.jpg, createdBy=3f88101689, createdName=princesun083, createdTime=Mon Feb 04 00:00:00 CST 2019, time=2019-02-04, status=1, ipAttribution=)]
    2019-02-04 princesun083

    Good，今年估计5.8分，还会涨，cancer领域将有一席之地

    1

    展开1条回复
共85条页码: 2/9页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分